Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | F7 | P08709 | 2/20 | 0.35 |
| ▸ | F3 | P13726 | 2/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.34 |
| ▸ | BCKDK | O14874 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196740 | 0.83 | PARP1 (0.45) | TSHRALDH1A1TP53CASP1SMN1; SMN2 | |
| SCHEMBL7574859 | 0.81 | FSCN1 (0.35) | TSHRALDH1A1TP53CASP1SMN1; SMN2 | |
| SCHEMBL3278559 | 0.79 | ALDH1A1 (0.45) | ALDH1A1ALOX15NPC1RAB9ASRD5A2 | |
| SCHEMBL27648859 | 0.78 | ALDH1A1 (0.33) | TSHRALDH1A1TP53CASP1SMN1; SMN2 | |
| SCHEMBL6204339 | 0.76 | ALDH1A1 (0.49) | ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL10388530 | 0.76 | ALOX15 (0.41) | ALDH1A1SMN1; SMN2ALOX15NPC1RAB9A | |
| SCHEMBL10388340 | 0.76 | ALDH1A1 (0.38) | TSHRALDH1A1SMN1; SMN2ALOX15KDM4E | |
| SCHEMBL7584139 | 0.76 | HPGD (0.40) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1867402 | 0.76 | ABL1 (0.46) | ALDH1A1CASP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5857066 | 0.76 | KDM4E (0.42) | TSHRALDH1A1TP53SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| CN-113105411-A | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-110330465-A | Hydrazone amide derivatives and its application in preparation prevention and treatment alopecia agent | 深圳市三启药物开发有限公司 | 2019-10-15 | — | — | CN | claimed |
| CN-110229118-A | Hydrazone amide derivatives and its preparing the application in osteosporosis resistant medicament | 深圳市三启药物开发有限公司 | 2019-09-13 | — | — | CN | claimed |
| EP-1270000-A2 | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| EP-0963755-A2 | Use of benzopyranes for preventing allograft rejection | Pfizer Products Inc. (US) | 1999-12-15 | — | — | EP | claimed |
| EP-0943339-A2 | Method of preventing allograft rejection | Pfizer Products Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| JP-2765757-B2 | — | — | 1998-06-18 | — | — | JP | claimed |
| EP-0836850-A2 | Method of preventing allograft rejection | PFIZER INC. (US) | 1998-04-22 | — | — | EP | claimed |
| US-5684046-A | LEUKOTRIENE B4 ANTAGONIST AS ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | PFIZER INC (US) | 1997-11-04 | — | — | US | claimed |
| EP-0623123-B1 | Benzopyran and related LTB4-antagonists | PFIZER (US) | 1997-04-23 | — | — | EP | claimed |
| US-5552435-A | ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS | PFIZER INC. (US) | 1996-09-03 | — | — | US | claimed |
| EP-0623123-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | claimed |
| WO-1993015067-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | claimed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | claimed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | claimed |
| CN-113105411-B | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-113105411-A | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-110330465-B | Hydrazone amide derivative and application thereof in preparation of alopecia prevention and treatment medicines | 深圳市三启药物开发有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-110229118-B | Hydrazone amide derivative and application thereof in preparation of anti-osteoporosis drugs | 深圳市三启药物开发有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-110330465-A | Hydrazone amide derivatives and its application in preparation prevention and treatment alopecia agent | 深圳市三启药物开发有限公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-110229118-A | Hydrazone amide derivatives and its preparing the application in osteosporosis resistant medicament | 深圳市三启药物开发有限公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2619200-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8394848-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8383670-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2477982-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012040511-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7906553-B2 | Substituted thiophene modulators of intracellular calcium | CALCIMEDICA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-1537075-B1 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH AS (DK) | 2009-07-01 | — | — | EP | disclosed |
| CN-100391928-C | Method for removing impurities from oxidation products | GEN ELECTRIC (US) | 2008-06-04 | — | — | CN | disclosed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
| CN-1470491-A | Method for removing impurities from oxidation products | ͨ�õ�����˾ | 2004-01-28 | — | — | CN | disclosed |
| EP-1270000-A2 | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| EP-0963755-A2 | Use of benzopyranes for preventing allograft rejection | Pfizer Products Inc. (US) | 1999-12-15 | — | — | EP | disclosed |
| EP-0943339-A2 | Method of preventing allograft rejection | Pfizer Products Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5948813-A | Method of preventing allograft rejection | PFIZER INC. (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| EP-0836850-A2 | Method of preventing allograft rejection | PFIZER INC. (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| CN-1118595-A | Anthranilic acid derivative | EISAI CO LTD (JP) | 1996-03-13 | — | — | CN | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-4906662-A | Phenol derivatives, their preparation and the use thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0263229-A1 | Phenol derivatives, their preparation and the use thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1988-04-13 | — | — | EP | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | disclosed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | disclosed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | TSHR 4363/4885ALDH1A1 1538/4885TP53 3348/4885 |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SOST, HDAC5, PTH1R | TSHR 1218/4885ALDH1A1 644/4885TP53 4852/4885 |
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | TSHR 1901/4885ALDH1A1 1776/4885TP53 644/4885 |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | FH, HDGF, HRH4 | TSHR 1288/4885ALDH1A1 652/4885TP53 3487/4885 |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALDH1A1 4409/4885TP53 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.